Cohort Description

CHARTER ENROLLMENT (2003-2007)

CHARTER recruited ~1600 HIV-infected participants at varying stages of disease and with differing histories of antiretroviral treatment into the Cross-sectional Study. Participants in this study received comprehensive neuromedical and neurobehavioral assessments.

In addition a subset of 652 participants entered a Longitudinal Pathogenesis Study and were evaluated semi-annually. The cases were selected on the basis of identified groups of interest (defined as groups of participants with characteristics whose long term follow-up would shed additional light on important questions in regard to neuroAIDS in the era of HAART).

CHARTER Enrollment by Performance Site Participant Groups

  • ARV Group (n = 543)
  • Peripheral Neuropathy (n = 203)
  • Metabolic Complications (n = 91)
  • Neuroimaging (n = 150)
  • Viral Genetics (n = 42)
  • Acute and Early Infection (n = 50)

 

OPTION PERIOD COHORT (2007-2010)

300 participants (50 per site) were selected from the Longitudinal Study (N=600). Assessments will occurred every six months. This cohort was selected to address aims related to host genetics, viral genetics, worsening peripheral neuropathy, and progression of abnormal white matter.

 

Number of Subjects and Visits in Option Years 6-8
  YEAR 6 YEAR 7 YEAR 8
Visits across all sites 577 490 417
Visits per site 96 82 69
Subjects at beginning of each year
(adjusting for anticipated attrition)
300 255 217